Celularity Inc. - Class A Common Stock
Celularity Inc. - Class A Common Stock
Acción · US1511902041 · CELU (XNAS)
Resumen Indicadores financieros
2,07 USD
7,81 % 0,15 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 19:59

Cotizaciones actuales de Celularity Inc. - Class A Common Stock

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
CELU
USD
06.06.2025 19:59
2,07 USD
1,92 USD
+7,81 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % -2,36 % 23,58 % 61,72 % -10,78 % -36,31 % -97,93 %

Perfil de la empresa para Celularity Inc. - Class A Common Stock Acción

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Datos de la empresa

Nombre Celularity Inc. - Class A Common Stock
Empresa Celularity Inc.
Símbolo CELU
Sitio web https://www.celularity.com
Mercado principal XNAS NASDAQ
ISIN US1511902041
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Robert Joseph Hariri M.D., Ph.D.
Capitalización de mercado 37 Mio
País Estados Unidos de América
Moneda USD
Empleados 0,1 T
Dirección 170 Park Avenue, 07932 Florham Park
Fecha de OPV 2019-08-08

Cambios de identificador

Fecha De A
19.07.2021 GXGX CELU

Símbolos de cotización

Nombre Símbolo
NASDAQ CELU

Otras acciones

Los inversores que tienen Celularity Inc. - Class A Common Stock también tienen las siguientes acciones en su cartera:
RESIDENTIAL MORTGAGE SECURITIES 4 PLC MTG EARLY RED CERTS 2038 £(BR)(REG S)
RESIDENTIAL MORTGAGE SECURITIES 4 PLC MTG EARLY RED CERTS 2038 £(BR)(REG S) Bono
T. Rowe Price International Stock Fund Class R
T. Rowe Price International Stock Fund Class R Fondo
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025